Peter Goadsby
FRS FRACP FRCP is an Australian neuroscientist who is Director of the
National Institute for Health Research
The National Institute for Health and Care Research (NIHR) is the British government’s major funder of clinical, public health, social care and translational research. With a budget of over £1.2 billion in 2020–21, its mission is to "impr ...
-
Wellcome Trust
The Wellcome Trust is a charitable foundation focused on health research based in London, in the United Kingdom. It was established in 1936 with legacies from the pharmaceutical magnate Henry Wellcome (founder of one of the predecessors of Glaxo ...
King’s Clinical Research Facility and Professor of Neurology at
King's College London.
His research has focused particularly on the mechanism and alleviation of migraine and cluster headaches.
Personal life and education
Goadsby was born in Australia in 1950.
He attended a secondary school that did not have high academic ambitions for the pupils. This made him determined to follow an academic course. He was interested in politics from a young age, and was planning to study economics at university. However, after an argument with his mother, a mathematics teacher, he applied to study medicine, and was accepted by
University of New South Wales
The University of New South Wales (UNSW), also known as UNSW Sydney, is a public research university based in Sydney, New South Wales, Australia. It is one of the founding members of Group of Eight, a coalition of Australian research-intensiv ...
.
As an undergraduate he met
James W. Lance and became interested in the area of experimental science applied to neurology, especially migraine.
Career
Goadsby's research has focused on headaches, trying to understand their mechanisms and how to provide better treatments. His work has especially addressed the causes of
migraine and
cluster headaches. His research led him to hypothesise that migraine might not be a vascular disease, as was then accepted, or psychosomatic and caused by stress. Instead, he and colleagues developed evidence that it had a nerve-based mechanism that resulted in the pain and other symptoms.
Their work in the 1980s led to the discovery of the mechanism that starts a migraine, involved
the calcitonin gene-related peptide, CGRP, a peptide involved in
neuronal communication.
This provided a new target for drugs, namely those that could interfere with the interaction of CGRP and its
receptor
Receptor may refer to:
* Sensory receptor, in physiology, any structure which, on receiving environmental stimuli, produces an informative nerve impulse
*Receptor (biochemistry), in biochemistry, a protein molecule that receives and responds to a ...
. As a result, the
gepants such as
atogepant have been developed and introduced to clinical use.
He was also part of a group that in a clinical trial over six months showed, for the first time, that a
monoclonal antibody
A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell Lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
Monoclonal antibodies ...
could significantly reduce frequency and effects of migraine.
Several have been introduced into clinical use for those with chronic migraine.
Erenumab
Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection.
Erenumab, which was developed by Amg ...
was approved for use in the USA (in 2018),
Scotland from 2019, England (from 2021),
and other countries.
He trained in neurophysiology with
David Burke. He subsequently trained, worked and studied with Don Reis at Cornell, USA; Jacques Seylaz at Universite VII, Paris, and post-graduate neurology training at the
Institute of Neurology
The UCL Queen Square Institute of Neurology is an institute within the Faculty of Brain Sciences of University College London (UCL) and is located in London, United Kingdom. Together with the National Hospital for Neurology and Neurosurgery, an ...
, London with
C David Marsden,
Andrew Lees,
Anita Harding and
W Ian McDonald. He later returned to Australia. He joined the University of New South Wales and became a consultant neurologist at the
Prince of Wales Hospital, Sydney
The Prince of Wales Hospital is a 440-bed major public teaching hospital located in Sydney's eastern suburb of Randwick, providing a full range of hospital services to the people of New South Wales, Australia. The hospital has strong ties to th ...
. He was later appointed a Wellcome Senior Research Fellow at the Institute of Neurology and Professor of Clinical Neurology and Honorary Consultant Neurologist at the
National Hospital for Neurology and Neurosurgery
The National Hospital for Neurology and Neurosurgery (informally the National Hospital or Queen Square) is a neurological hospital in Queen Square, London. It is part of the University College London Hospitals NHS Foundation Trust. It was the ...
, London until 2007.
Goadsby was Professor of Neurology, at University of California, San Francisco, 2007-2013. He is also an Honorary Consultant Neurologist at the
Great Ormond Street Hospital
Great Ormond Street Hospital (informally GOSH or Great Ormond Street, formerly the Hospital for Sick Children) is a children's hospital located in the Bloomsbury area of the London Borough of Camden, and a part of Great Ormond Street Hospit ...
for Sick Children, UK and Professor of Neurology, University of California, Los Angeles.
Awards
In March 2021 Goadsby and his collaborators Lars Edvinsson, Michael Moskowitz and Jes Olesen were awarded the Brain Prize 2021 for their work on the causes and treatment of migraine. The prize is 10 million Danish kroner.
He was elected a
Fellow of the Royal Society
Fellowship of the Royal Society (FRS, ForMemRS and HonFRS) is an award granted by the judges of the Royal Society of London to individuals who have made a "substantial contribution to the improvement of natural knowledge, including mathemat ...
in 2022.
Publications
Goadsby is the author or co-author of many scientific publications and several books and book chapters. These include:
* Peter J. Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H. Bonner, Feng Zhang, Sandhya Sapra, Hernan Picard, Daniel D. Mikol, and Robert A. Lenz (2017
A controlled trial of erenumab for episodic migraine ''New England Journal of Medicine.'' 377 2123-2132
* A. May, J. Ashburner, C. Büchel, D.J. McGonigle, K.J. Friston, R.S.J. Frackowiak & P.J. Goadsby (1999
Correlation between structural and functional changes in brain in an idiopathic headache syndrome.Nature Medicine 5 836–838
* James W. Lance ''Mechanism and Management of Headache'' (London: Butterworths, c. 1969; 3rd ed., 1978; 4th ed., 1982; 6th ed., Boston and Oxford: Butterworth Heinemann, 1999; 7th ed., Oxford: Elsevier Butterworth-Heinemann, 2005). With Peter J. Goadsby as joint editor for 6th ed.
* P. Goadsby, L Edvinsson and Ekman (1990
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.''Annals of Neurology'' 28 (2) 183-187
References
{{DEFAULTSORT:Goadsby, Peter
1950 births
Australian neuroscientists
Fellows of the Royal Society
Academics of King's College London
University of New South Wales alumni
NIHR Senior Investigators
Living people